Major finding: A GPC2-targeting antibody–drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.
Approach: An RNA-seq pipeline identifies candidate cell-surface targets specifically expressed in neuroblastoma.
Impact: Immunotherapeutic GPC2 targeting may be beneficial in high-risk neuroblastoma and other embryonal tumors.
